Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer

被引：22
|
作者：
Boeck, Stefan [1 ]
Heinemann, Volker [1 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Klinikum Grosshadern, Dept Internal Med 3, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 07期
关键词：
D O I：
10.1200/JCO.2007.15.3304
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1178 / 1179
页数：2
相关论文
共 50 条
  • [1] Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer - Reply
    Kulke, Matthew H.
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) : 1179 - 1179
  • [2] Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer
    Altwegg, Romain
    Ychou, Marc
    Guillaumon, Vanessa
    Thezenas, Simon
    Senesse, Pierre
    Flori, Nicolas
    Mazard, Thibault
    Caillo, Ludovic
    Faure, Stephanie
    Samalin, Emmanuelle
    Assenat, Eric
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (12) : 1357 - 1364
  • [3] Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer
    Romain Altwegg
    Marc Ychou
    Vanessa Guillaumon
    Simon Thezenas
    Pierre Senesse
    Nicolas Flori
    Thibault Mazard
    Ludovic Caillo
    Stéphanie Faure
    Emmanuelle Samalin
    Eric Assenat
    [J]. World Journal of Gastroenterology, 2012, (12) : 1357 - 1364
  • [4] What Else in Gemcitabine-Pretreated Advanced Pancreatic Cancer? An Update of Second Line Therapies
    Petrelli, Fausto
    Borgonovo, Karen
    Ghilardi, Mara
    Cabiddu, Mary
    Barni, Sandro
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2010, 5 (01) : 43 - 56
  • [5] Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer
    Boeck, Stefan
    Wilkowski, Ralf
    Bruns, Christiane J.
    Issels, Rolf D.
    Schulz, Christoph
    Moosmann, Nicolas
    Laessig, Dorit
    Haas, Michael
    Golf, Alexander
    Heinemann, Volker
    [J]. ONCOLOGY, 2007, 73 (3-4) : 221 - 227
  • [6] Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
    Tsavaris, N
    Kosmas, C
    Skopelitis, H
    Gouveris, P
    Kopteridis, P
    Loukeris, D
    Sigala, F
    Zorbala-Sypsa, A
    Felekouras, E
    Papalambros, E
    [J]. INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) : 369 - 375
  • [7] Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
    Brell, Joanna M.
    Matin, Khalid
    Evans, Terry
    Volkin, Robert L.
    Kiefer, Gauri J.
    Schlesselman, James J.
    Dranko, Shelley
    Rath, Linda
    Schmotzer, Amy
    Lenzner, Diana
    Ramanathan, Ramesh K.
    [J]. ONCOLOGY, 2009, 76 (04) : 270 - 274
  • [8] Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
    Nicolas Tsavaris
    Christos Kosmas
    Helias Skopelitis
    Panagiotis Gouveris
    Petros Kopteridis
    Dioynissis Loukeris
    Frantzeska Sigala
    Alexandra Zorbala-Sypsa
    Evangelos Felekouras
    Efstathios Papalambros
    [J]. Investigational New Drugs, 2005, 23 : 369 - 375
  • [9] Second line treatment with 5-fluorouracil and folonic acid in gemcitabine-pretreated advanced pancreatic cancer
    Kheira, Rekai
    Larbaoui, Blaha
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [10] SECOND-LINE CHEMOTHERAPY IN GEMCITABINE PRETREATED ADVANCED PANCREATIC CANCER: ANALYSES ON PROGNOSTIC AND PREDICTIVE FACTORS
    Cha, Y.
    Oh, D.
    Lee, S.
    Kim, D.
    Im, S.
    Kim, T.
    Heo, D. S.
    Bang, Y.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 181 - 181
12345